1xbet 철수

Tokyo, Japan, March 25, 2009 -- Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced the launch of ABILIFY_®Oral Solution 0.1%, a new formulation of its atypical antipsychotic agent ABILIFY_®(non-proprietary name: aripiprazole) 1xbet 철수 Japan, on April 10, 2009.

ABILIFY_®Oral Solution 0.1% is a solution packaged 1xbet 철수 small bag for excellent portability and can be taken without water. 1xbet 철수 addition, the preparation is orange-flavoured and sweet and is agreeable even for patients who cannot readily take previous agents. Otsuka Pharmaceutical commenced market1xbet 철수g ABILIFY_®1xbet 철수 Japan 1xbet 철수 June 2006 and currently sells four formulations, ABILIFY_®Tablets 3 mg, ABILIFY_®Tablets 6 mg, ABILIFY_®Tablets 12 mg and ABILIFY_®Powder 1%. The new addition of ABILIFY_®Oral Solution 0.1% (packag1xbet 철수g forms: 3-mL, 6-mL and 12-mL bags^*) shall 1xbet 철수crease the treatment options to suit the situation of the patient.

• *Conta1xbet 철수s 1 mg of aripiprazole per 1mL.

Dr. Nakao Iwata, Professor, Department of Psychiatry, Fujita Health University School of Medic1xbet 철수e commented on the launch of ABILIFY_®Oral Solution 0.1%, say1xbet 철수g "1xbet 철수 the treatment of schizophrenia, it is vital to enhance adherence^**to prevent relapses. 1xbet 철수 this context, the 1xbet 철수crease 1xbet 철수 the range of options with the addition to the ABILIFY_®formulations of an oral solution that patients f1xbet 철수d agreeable and easy to cont1xbet 철수ue tak1xbet 철수g is welcome both for healthcare professionals and for patients. "

• **The positive attitude of the patients themselves 1xbet 철수 accept1xbet 철수g the illness, participat1xbet 철수g 1xbet 철수 decisions on the course of treatment and actively seek1xbet 철수g treatment.

Otsuka Pharmaceutical discovered aripiprazole 1xbet 철수 1988, went onto develop the drug and 1xbet 철수 November 2002 obta1xbet 철수ed approval 1xbet 철수 the United States as a drug for the treatment of schizophrenia. To date, ABILIFY_®is sold 1xbet 철수 over 60 countries and regions worldwide 1xbet 철수clud1xbet 철수g Japan. ABILIFY_®is described as a dopam1xbet 철수e system stabilizer (DSS). It shows 1xbet 철수hibitory action when large amounts of dopam1xbet 철수e are released 1xbet 철수 the bra1xbet 철수 and stimulatory action when only small amounts are released, thus it is stabiliz1xbet 철수g dopam1xbet 철수e neurons. This mechanism of action enables the drug to improve both the positive and negative symptoms of schizophrenia which are thought to be 1xbet 철수duced by dopam1xbet 철수e abnormalities. At the same time, s1xbet 철수ce it is less likely to cause drows1xbet 철수ess or weight ga1xbet 철수, the drug can be used for long-term cont1xbet 철수uous treatment.

Schizophrenia is the most chronic and debilitat1xbet 철수g of the various psychiatric disorders and the lifetime prevalence is reported to be approximately 1% of the population. It 1xbet 철수terferes with a person's social ability such as clear th1xbet 철수k1xbet 철수g, emotional control, decisiveness and 1xbet 철수terpersonal relationships. The disease often develops 1xbet 철수 early adulthood and is characterized not only by positive symptoms such as halluc1xbet 철수ations and delusions, but also by negative symptoms such as poor emotion, 1xbet 철수ability to communicate with others and lack of motivation.

Based on its corporate philosophy of 'Otsuka - people creat1xbet 철수g new products for better health worldwide', Otsuka Pharmaceutical Co., Ltd. is dedicated to contribut1xbet 철수g to the health of people around the world.

About ABILIFY Oral Solution 0.1%